TOKYO, JAPAN, January 14, 2026 / EINPresswire.com / — LOTTE Holdings, Co., Ltd. (Tokyo, Japan; CEO: Genichi Tamatsuka, ...

The UK-based multinational, science-led biopharmaceutical company AstraZeneca on Thursday announced $15 billion investment in ...

Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S.

In this Opinion piece, Brandon Pence takes us behind the scenes of biopharma to explore its evolution and logistical ...

ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to ...

GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving ...

Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing ...

MicuRx Pharmaceuticals, Inc. (MicuRx), a clinical-stage biopharmaceutical company focused on developing novel anti-infective ...

FirstWord Pharma’s 2026 list aggregates core pipeline assets from the world’s leading pharmaceutical companies. Alongside ivonescimab, the list highlights transformative therapies such as Eli Lilly’s ...

Kalaris Therapeutics, Inc. (NASDAQ: KLRS) ('Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its ...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity First-in-class, oral PKM2 modulator, SYX-5219, has the ...